What percentage of patients experience spotting or continue to have menstrual cycles after Nexplanon (etonogestrel) implantation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bleeding Patterns After Nexplanon Insertion

Approximately 78% of Nexplanon users will experience some form of spotting or continued menstrual bleeding, with only 22% achieving complete amenorrhea. 1, 2

Specific Bleeding Pattern Breakdown

Based on pooled analysis from 11 clinical trials of etonogestrel implant users, the bleeding patterns break down as follows:

  • 22% experience amenorrhea (no bleeding)
  • 34% have infrequent spotting (less than 3 bleeding episodes per 90 days)
  • 7% report frequent bleeding (more than 5 episodes per 90 days)
  • 18% experience prolonged bleeding (episodes lasting >14 days)

This means 78% of patients will have some form of bleeding or spotting, while only 22% will have no bleeding at all. 1

Detailed Clinical Data from FDA Label

The FDA-approved drug label provides granular data on bleeding patterns over 90-day intervals 2:

Days of bleeding/spotting per 90-day period:

  • 0 days: 17-24% of patients
  • 1-7 days: 12-15% of patients
  • 8-21 days: 30-37% of patients
  • >21 days: 33-35% of patients

Average bleeding burden: Women experienced 17.7 days of bleeding or spotting every 90 days (approximately 20% of days).

Predictive Value of Early Bleeding Patterns

The bleeding pattern in the first 3 months strongly predicts future patterns. Women with favorable bleeding initially (amenorrhea, infrequent, or normal frequency without prolonged bleeding) have an 84.6% chance of maintaining favorable patterns, while those with unfavorable initial patterns have approximately 40-50% chance of improvement. 3, 4

Clinical Implications

Pre-Insertion Counseling Priorities

Counsel patients that:

  • Most women (78%) will experience some bleeding changes
  • The first 3 months predict long-term patterns
  • Bleeding irregularities are not harmful
  • Heavy or prolonged bleeding is uncommon (occurs in <20%)

Risk Factors for Bothersome Bleeding

Patients at higher risk for problematic bleeding include those with 5:

  • Previously irregular menses (OR 1.36-1.41)
  • Seeking implant primarily for menstrual management (OR 1.67)
  • No prior progestin injection or implant use

Management Approach

For irregular bleeding: If no underlying pathology (pregnancy, STD, uterine conditions), consider 1:

  • NSAIDs for 5-7 days during bleeding episodes
  • Low-dose combined oral contraceptives or estrogen for 10-20 days (if medically eligible)

Important caveat: Medication management of bleeding is associated with nearly 2-fold higher discontinuation rates at 1 year (HR 1.98), though over 50% of treated patients still continue use for 3 years. 5

For amenorrhea: Reassurance only—no treatment needed. Rule out pregnancy if pattern changes abruptly. 1

Discontinuation Rates

Bleeding irregularities account for 11.1% of discontinuations, with irregular bleeding (10.8%) being the primary reason rather than amenorrhea (0.3%). 2 Initial favorable bleeding patterns result in significantly lower discontinuation rates: 3.7% vs 12.7% in year 1, and 2.5% vs 16.5% in year 2. 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.